Investors of Soleno Therapeutics Face Potential Class Action Over Losses and Alleged Misrepresentations
In a significant development for investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO), the national shareholder rights law firm Hagens Berman has issued a vital reminder concerning an ongoing securities class action. Investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025, and suffered considerable losses during this period have the opportunity to take legal action. The firm is urging affected shareholders to submit their losses before the impending deadline of May 5, 2026, to petition as lead plaintiff in the case.
The case at hand, officially named City of Pontiac Police Fire Ret. Sys. v. Soleno Therapeutics, Inc., et al., has drawn attention due to serious allegations against the company regarding its flagship product, VYKAT™ XR (DCCR), intended for treating Prader-Willi syndrome (PWS). Shareholders are primarily concerned about the consistency of the information provided by Soleno concerning the safety and efficacy of this drug.
The complaint outlines that Soleno made several commitments about the commercial viability of DCCR while purportedly failing to disclose critical safety risks that included serious side effects such as excess fluid retention and potential heart issues in children. Additionally, accusations of inflated launch metrics suggest that the company's claims regarding the success of DCCR’s market launch were manipulated by undisclosed influences rather than genuine consumer demand. These factors have raised significant red flags concerning the integrity of Soleno's data and reporting practices.
One of the core claims in the class action revolves around the allegation that Soleno intentionally concealed safety concerns associated with DCCR, which may jeopardize the health of vulnerable patients. These claims were highlighted in a report released by activist short seller Scorpion Capital, which documented patient adverse reactions and questioned the validity of Soleno’s clinical trial results.
The fallout from these revelations has been substantial. Following the publication of the Scorpion Capital report on August 15, 2025, shares of Soleno witnessed an immediate decline, emphasizing the market’s reaction to perceived safety risks associated with DCCR. Furthermore, when Soleno reported its Q3 results on November 4, 2025, it was confirmed that the anticipated launch of DCCR had not met initial expectations, leading to another significant drop in stock prices.
Investors are reminded that the deadline to apply as lead plaintiff is fast approaching; those who purchased Soleno stock during the Class Period must act swiftly if they want to participate in the class suit. Hagens Berman is conducting an investigation into the allegations and invites anyone with pertinent information to come forward. Whistleblowers are encouraged to report non-public information about the company’s practices that could aid in this investigation. The firm may offer rewards to whistleblowers who provide information leading to successful recoveries under the SEC's new whistleblower program.
Hagens Berman is known for its commitment to corporate accountability, having secured over $2.9 billion in settlements for investors and consumers in various legal battles. To learn more about the ongoing investigation or to discuss potential claims, investors can contact the firm at 844-916-0895 or visit their website for more information.
As the case develops, Soleno Therapeutics investors must remain vigilant and informed about their rights and the steps they can take to seek justice following the alleged misrepresentations that resulted in financial losses.
Background of the Case
The case at hand, officially named City of Pontiac Police Fire Ret. Sys. v. Soleno Therapeutics, Inc., et al., has drawn attention due to serious allegations against the company regarding its flagship product, VYKAT™ XR (DCCR), intended for treating Prader-Willi syndrome (PWS). Shareholders are primarily concerned about the consistency of the information provided by Soleno concerning the safety and efficacy of this drug.
The complaint outlines that Soleno made several commitments about the commercial viability of DCCR while purportedly failing to disclose critical safety risks that included serious side effects such as excess fluid retention and potential heart issues in children. Additionally, accusations of inflated launch metrics suggest that the company's claims regarding the success of DCCR’s market launch were manipulated by undisclosed influences rather than genuine consumer demand. These factors have raised significant red flags concerning the integrity of Soleno's data and reporting practices.
Allegations of Misrepresentation
One of the core claims in the class action revolves around the allegation that Soleno intentionally concealed safety concerns associated with DCCR, which may jeopardize the health of vulnerable patients. These claims were highlighted in a report released by activist short seller Scorpion Capital, which documented patient adverse reactions and questioned the validity of Soleno’s clinical trial results.
The fallout from these revelations has been substantial. Following the publication of the Scorpion Capital report on August 15, 2025, shares of Soleno witnessed an immediate decline, emphasizing the market’s reaction to perceived safety risks associated with DCCR. Furthermore, when Soleno reported its Q3 results on November 4, 2025, it was confirmed that the anticipated launch of DCCR had not met initial expectations, leading to another significant drop in stock prices.
Critical Deadlines and Legal Actions
Investors are reminded that the deadline to apply as lead plaintiff is fast approaching; those who purchased Soleno stock during the Class Period must act swiftly if they want to participate in the class suit. Hagens Berman is conducting an investigation into the allegations and invites anyone with pertinent information to come forward. Whistleblowers are encouraged to report non-public information about the company’s practices that could aid in this investigation. The firm may offer rewards to whistleblowers who provide information leading to successful recoveries under the SEC's new whistleblower program.
Hagens Berman is known for its commitment to corporate accountability, having secured over $2.9 billion in settlements for investors and consumers in various legal battles. To learn more about the ongoing investigation or to discuss potential claims, investors can contact the firm at 844-916-0895 or visit their website for more information.
As the case develops, Soleno Therapeutics investors must remain vigilant and informed about their rights and the steps they can take to seek justice following the alleged misrepresentations that resulted in financial losses.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.